Although HDAC inhibition has been reported to increase PD-1 blockade efficacy in melanoma and lung adenocarcinoma [9, 20], its potential role in breast cancer as immune modulator and the mechanism promoting such strategy has not been investigated. The gene discussed is PDCD1; the disease is breast carcinoma.